Evidence map›Paper›PMID 40500108›Full record

ArticleJournal for immunotherapy of cancer2025

Low-dose photodynamic therapy promotes vascular E-selectin expression in chest malignancies, improving immune infiltration and tumor control.

Louis-Emmanuel Chriqui, Damien Nicolas Marie, Alexandros Sifis, Christophe Gattlen, Matteo Ortolini, Yameng Hao, Olga De Souza Silva, Etienne Abdelnour-Berchtold, Michel Gonzalez, Thorsten Krueger and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Louis-Emmanuel Chriqui *Division of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0009-0003-1177-487X
Damien Nicolas Marie *Division of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Alexandros SifisDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Christophe GattlenDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Matteo OrtoliniDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Yameng HaoDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Olga De Souza SilvaDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Etienne Abdelnour-BerchtoldDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Michel GonzalezDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Thorsten KruegerDivision of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Lucas LiaudetDivision of Adult Intensive Care Medicine, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Etienne MeylanLung Cancer and Immuno-Oncology Laboratory, Bordet Cancer Research Laboratories, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Anderlecht, Belgium.
Sabina BerezowskaInstitute of Pathology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Michel ChristodoulouDivision of General Thoracic Surgery, Valais Hospital, Sion, Switzerland.
Tereza LosmanovaInstitute of Tissue Medicine and Pathology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Ren Wang PengDivision of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Thomas Michael MartiDivision of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Johanna JoyceAgora Cancer Research Center Lausanne, Lausanne, Switzerland.
Sabrina Cavin *Division of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Jean Yannis Perentes *Division of Thoracic Surgery, Department of Surgery, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland jean.perentes@chuv.ch.ORCID http://orcid.org/0000-0001-7918-0793

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChest malignancies such as non-small cell lung cancer (NSCLC) or pleural mesothelioma (PM) have an ominous prognosis. Photodynamic therapy (PDT) of NSCLC and PM improves patient survival, but the precise underlying mechanism remains unknown. Here, we hypothesized that low-dose PDT (L-PDT) alters the expression of tumor endothelial cell adhesion molecules favoring immune cell recruitment and tumor control. We explored this hypothesis in two mouse models of NSCLC and PM. We validated our findings in 82 PM patient samples.

methodsWe assessed, in C56BL/6 mice bearing 344SQ-NSCLC and in BALB/c mice bearing AB12-PM, how L-PDT (400 μg/kg Visudyne administered intravenously, irradiance: 50 mW/cm

resultsL-PDT induced vascular E-selectin in both NSCLC and PM, which enhanced granzyme B+/CD3+/CD8+ lymphocyte infiltration and improved tumor control. Blockade of E-selectin or immunodepletion of CD8+ lymphocytes abrogated the L-PDT-mediated cancer regression. Moreover, canonical NF-κB pathway blockade impaired enhanced vascular E-selectin expression and CD8+ T cells infiltration in tumors following L-PDT. In human malignant pleural mesothelioma samples, we found a correlation between vascular E-selectin and CD8+ T cell infiltration, which was associated with improved patient outcome.

conclusionL-PDT remodels the vasculature of chest tumors and favors a cytotoxic immune microenvironment promoting tumor control. This approach could complement current immunotherapy approaches in these malignancies.

Indexed as

Carcinoma, Non-Small-Cell LungE-SelectinLung NeoplasmsMesotheliomaPhotochemotherapyPleural NeoplasmsAnimalsCell Line, TumorFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiceMice, Inbred BALB CPhotosensitizing AgentsTumor MicroenvironmentE-SelectinPhotosensitizing Agentsimmune checkpoint inhibitorimmunotherapylung cancermesotheliomasurgery

Identifiers

PMID40500108
PMCPMC12161339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.